InVivo Therapeutics, a medical device company focused on developing technologies for spinal cord injuries, has posted a net loss of $1.28 million for the first quarter 2011, representing a 181.5 percent increase in net loss compared to the same quarter last year, according to a company news release.
Operating expenses also increased by a little more than $1 million in Q1 of 2011 compared to Q1 of 2010 due to investments toward a planned human clinical trial of its biopolymer scaffolding device for spinal cord injuries. Part of the increased operating expenses was also due to incurred costs associated with public company practices, according to the news release.
Read the company news release about InVivo Therapeutics' financial results (pdf).
Related Articles on Device Company Financial Results:
SANUWAVE Posts Q1 $252K Revenue, 76% Increase
TranS1 Reports $5.1M in Q1 Revenues, 24% Decrease
DJO Global Reports $249.7M in Q1 Net Sales
Operating expenses also increased by a little more than $1 million in Q1 of 2011 compared to Q1 of 2010 due to investments toward a planned human clinical trial of its biopolymer scaffolding device for spinal cord injuries. Part of the increased operating expenses was also due to incurred costs associated with public company practices, according to the news release.
Read the company news release about InVivo Therapeutics' financial results (pdf).
Related Articles on Device Company Financial Results:
SANUWAVE Posts Q1 $252K Revenue, 76% Increase
TranS1 Reports $5.1M in Q1 Revenues, 24% Decrease
DJO Global Reports $249.7M in Q1 Net Sales